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Abstract
Introduction: The present study aims to evaluate the incidence, types, timing and risk factors in amiodarone (AMD)-induced thyroid 
dysfunction.
Material and methods: The study comprised 229 patients from an iodine-replete area (115 women, 114 men, mean age 63.8 ± 9.2 years), 
chronically treated with AMD. The cases were clinically investigated prior to, and during treatment, by thyroid 2D and color Doppler flow 
sonography, thyroid function tests (TSH, FT3, FT4), and antithyroid antibodies.
Results: Of 88 patients (38.4%) who developed thyroid dysfunction, 47 (20.5%) presented AMD-induced thyrotoxicosis (AIT) and 41 
(17.9%) AMD-induced hypothyroidism (AIH). There is an evident prevalence of subclinical AIH (29 cases), compared to subclinical AIT 
(three cases). Regarding clinical forms, these prevailed in AIT (44 patients) (p < 0.001, Fisher’s exact test). Thyrotoxic patients were clas-
sified in pathogenic types as follows: 11 cases as type 1, 15 cases as type 2, and 21 cases as mixed form. The most important risk factor 
for the development of thyroid dysfunction was represented by the underlying thyroid pathology. The patients with previous thyroid 
abnormalities (diffuse or nodular goitre and/or positive antithyroid antibodies) developed earlier thyroid dysfunction compared to those 
with an apparently normal thyroid gland. The thyroid dysfunction occurrence was heterogeneous (4–84 months). Thyrotoxicosis involved 
especially young ages, while AIH affected later years.The daily dose, the duration of the treatment and the cumulative dose of AMD do 
not represent risk factors in thyroid dysfunction development. The determination of serum AMD and desethylamiodarone concentrations 
does not offer benefits in the diagnosis and treatment of thyroid dysfunction.
Conclusions: In the present study, the incidence of AIH was similar to that reported in iodine-replete areas. The incidence of AIT was 
higher that previously reported, a fact underlining the importance of the proper screening and monitoring of patients. Cases with previous 
thyroid morphologic and/or immunologic abnormalities require frequent monitoring. (Pol J Endocrinol 2012; 63 (1): 2–9)
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Streszczenie
Wstęp: Badanie przeprowadzono w celu oceny zapadalności na zaburzenia czynności tarczycy indukowane amiodaronem (AMD).
Materiał i metody: Badanie obejmowało 229 chorych zamieszkujących region bogaty w jod (115 kobiet, 114 mężczyzn; średnia wieku 
63,8 ± 9,2 roku), długoterminowo leczonych AMD. Przed i w trakcie terapii u uczestników przeprowadzono ocenę kliniczną, badanie USG 
2D i techniką kolorowego doplera, testy czynności tarczycy (TSH, FT3, FT4) oraz oznaczono przeciwciała przeciwtarczycowe.
Wyniki: Spośród 88 chorych (38,4%), u których rozwinęły się zaburzenia czynności tarczycy, u 47 (20,5%) stwierdzono indukowaną AMD 
tyreotoksykozę (AIT), a u 41 (17,9%) — indukowaną AMD niedoczynność tarczycy (AIH).
W badanej grupie odnotowano zdecydowanie więcej przypadków subklinicznej AIH (29 przypadków) niż subklinicznej AIT (3 przy-
padków). Porównanie częstości jawnych klinicznie postaci zaburzeń czynności tarczycy wykazało przewagę AIT (44 chorych) (p < 0,001, 
dokładny test Fishera).
Osoby z tyreotoksykozą sklasyfikowano w zależności od typu patogenetycznego: 11 przypadków jako typ 1, 15 przypadków jako typ 2 
i 21 przypadków jako postać mieszaną.
Najważniejszym czynnikiem ryzyka rozwoju badanych zaburzeń były choroby tarczycy. U chorych, u których wcześniej stwierdzono 
nieprawidłowości w badaniach tarczycy (wole rozlane lub guzkowe i/lub obecność przeciwciał przeciwtarczycowych), zaburzenia czynności 
gruczołu rozwijały się wcześniej niż u osób, u których wyniki badań były prawidłowe.
Zaburzenia czynności tarczycy pojawiały się sie w różnym czasie (w ciągu 4–84 miesięcy). Tyreotoksykoza występowała głównie u osób 
młodych, natomiast AIH rozwijała sie w późniejszym wieku.
Dawka dobowa, czas trwania terapii i skumulowana dawka AMD nie stanowiły czynników ryzyka rozwoju zaburzeń czynności tarczycy. 
Określenie stężeń AMD i desetylamiodaronu w surowicy nie było pomocne w rozpoznaniu i leczeniu zaburzeń czynności tarczycy.
Wnioski: Zapadalność na AIH w badanej grupie była podobna, jak w innych regionach bogatych w jod. Liczba nowych przypadków 
AIT była większa niż opisywana wcześniej, co podkreśla znaczenie badań przesiewowych i monitorowania pacjentów. Zwłaszcza osoby 
z nieprawidłowościami w zakresie budowy tarczycy i zaburzeniami immunologicznymi wymagają częstych badań kontrolnych. (En-
dokrynol Pol 2012; 63 (1): 2–9)
Słowa kluczowe: amiodaron, zaburzenia czynności tarczycy, tyreotoksykoza, niedoczynność tarczycy
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Introduction
The present study regards a topic of general interest, 
because amiodarone (AMD)-induced thyroid dysfunc-
tion may be associated with significant morbidity and 
mortality.
AMD is a very widely used antiarrhythmic drug. 
Its structure resembles that of thyroid hormones, and 
hence some of its antiarrhythmic and toxic effects might 
be due to interactions with thyroid hormones nuclear 
receptors [1].
AMD and its major metabolite, desethylamiodarone 
(DEA) have a long half-life of 16 to 180 days [2].
Prolonged administration of AMD can be associated 
with numerous side effects, one of the commonest being 
thyroid dysfunction [3].
AMD affects the thyroid gland by its high iodine 
content (37% of its molecular weight) and/or direct toxic 
effect on thyroid cells [4].
In the evaluation of a patient chronically treated 
with AMD, its complex effects on the thyroid must be 
considered [5]. Hence, 30–40% of the subjects treated 
over three months might present altered laboratory 
tests, such as high-normal free T4 (as much as 40% 
above basal values) or low-normal free T3 associated 
with normal TSH [3].
Although most patients remain euthyroid during 
AMD treatment, 2–24% can develop thyroid dysfunc-
tion, ranging from asymptomatic altered laboratory 
findings to overt disease [6].
Most authors have reported a higher incidence of 
AMD-induced hypothyroidism (AIH) in iodine-suf-
ficient areas, with the incidence ranging from 6% in 
iodine-deficient regions to 13% in iodine-repleate zones 
[7, 8]. Amiodarone-induced thyrotoxicosis (AIT) is con-
sidered to prevail in iodine-deficient areas, where it 
exceeds 13% [9, 10]. These discrepancies of AIH and AIT 
incidences may be due to: different diagnostic criteria, 
various iodine intake, different monitoring schedules, 
or geographical differences [11].
Generally, AIH develops earlier than AIT, usually 
during the first 18 months of treatment [7, 12]. It can 
occur in patients with previous thyroid abnormalities, 
but also in those with apparently normal thyroids 
[13, 14].
The main risk factor is represented by chronic auto-
immune thyroiditis; 40% of patients who develop AIH 
present positive antithyroid antibodies. This suggests 
that iodine excess from AMD could unmask a pre-exist-
ing subclinical thyroid disease [15–17]. Other possible 
mechanisms have been described as being involved in 
AIH development [18, 19].
AIT predominates in men, probably due to a higher 
prevalence of cardiac diseases [20]. AIT is unpredictable, 
occurring any time during AMD treatment and even af-
ter drug interruption, because of its long half-life [2, 21].
The risk factors involved in AIT occurrence remain 
controversial. A pre-existing thyroid disease (nodular 
goitre, thyroid with functional autonomy) and a pre-
vious iodine deficiency are the main predisposing 
factors [22, 23]. Certain genes could also increase 
susceptibility [24].
AIT is classified arbitrarily into two major forms, 
based on clinical and laboratory parameters [25]. The 
differentiation into pathogenic forms is important for 
the therapeutic approach, although some studies sug-
gest that the subtype does not influence the outcome 
[26–28]. Type 1 is an iodine-induced hyperthyroid-
ism, developed in patients with previous thyroid 
abnormalities (latent Graves’ disease, nodular goitre). 
Type 2 represents a destructive form of thyroiditis, and 
occurs in subjects with previous apparently normal 
thyroid glands [2, 5].
Screening and monitoring of thyroid functionality in 
AMD-treated patients remains a subject for discussion, 
since a universal schedule is lacking. So far, several dif-
ferent guidelines have been proposed, one of the most 
widely accepted having been developed by the North 
American Society of Pacing and Electrophysiology in 
2000 [29].
Before introducing AMD treatment, the basal thy-
roid screening should include: clinical exam, thyroid 
ultrasound, and determination of serum TSH, FT3, FT4 
and antithyroid antibodies.
Some authors recommend endocrinological reevalu-
ation every six months without monitoring the initial 
three months of treatment with AMD [30]. Others 
consider necessary a first evaluation at three months 
after starting therapy, and regular monitoring every six 
months, or if a clinical suspicion of thyroid dysfunction 
arises [6].
The aims of the present study were to evaluate the 
prevalence, types, timing and risk factors in AMD-in-
duced thyroid dysfunction, in an iodine-sufficient 
region. 
Material and methods
Our study included 229 AMD chronically treated 
patients (115 women, 114 men, mean age 63.8 ± 9.2 
years). The subjects, from an iodine-replete area, 
were investigated in the Clinic of Endocrinology, 
Timisoara, Romania, in the period October 2004 to 
September 2010.
The study inclusion criteria were age over 18 years 
and AMD treatment over three months. Subjects with 
thyroid morphology abnormalities (diffuse or nodular 
goitre) or positive serum antithyroid antibodies, associ-
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ated with euthyroidism before AMD treatment, were 
included. 
Patients with severe heart failure, incessant ventricu-
lar tachyarrhythmia not controlled by medical therapy, 
uncorrected severe valvular abnormalities, complex 
congenital heart disease or severe systemic illness were 
excluded. Those diagnosed with thyroid dysfunction 
prior to AMD therapy were also excluded. 
Amiodarone-induced thyrotoxicosis (AIT) was 
defined as suppressed TSH (< 0.1 mU/L). Subclinical 
form presented normal serum T3 concentrations (total 
and free) and normal or high-normal total and free T4, 
without any clinical signs. Overt thyrotoxicosis showed 
elevated serum thyroid hormones. AIT was classified in 
two major forms. The diagnostic criteria for type 1 were 
as follows: diffuse or nodular goitre, increased thyroid 
vascularity in colour flow Doppler sonography, and 
positive antithyroid antibodies. AIT type 2 presented 
a normal thyroid volume or small goitre, no thyroid vas-
cularity, and no positive antithyroid antibodies. Cases 
with features common to both types were considered 
to be mixed forms [2].
Overt amiodarone-induced hypothyroidism (AIH) 
was ascertained by high values of serum TSH and low 
thyroxin values, while the subclinical form included per-
sistent slightly elevated TSH (4.5–20 mU/L) and normal 
or high-normal serum T4, with no clinical signs [30, 31].
The study was approved by the local ethics commit-
tee. All patients provided oral informed consent.
Thyroid gland volume, morphology and vascularisa-
tion were assessed using B-mode and colour Doppler 
ultrasonography. 
Serum TSH (third generation TSH, Architect i2000, 
Abbott Diagnostics), free T4, free T3 (CMIA, Architect 
i2000, Abbott Diagnostics), anti TPO antibodies (CMIA, 
Abbott Ax SYM System), antithyroglobulin antibodies 
(MEIA, Abbott Ax SYM System) and anti TSH receptor 
antibodies (TRAb) (Brahms Diagnostics, Berlin) were 
determined by commercial kits. Normal values were 
as follows: TSH 0.46–4.67 mU/L, FT3 1.71–3.71 pg/ml, 
FT4 0.71–1.85 ng/dL, TPO Ab < 12 U/L, Tg Ab < 35 U/L, 
and TRAb < 1U/L. 
Serum concentrations of AMD and DEA were deter-
mined using high-performance liquid chromatography 
(HPLC) (in Heidelberg, Germany). The given therapeu-
tic serum concentrations were 700–2,500 µg/L for AMD 
and 500–3,000 µg/L for DEA.
Statistical analysis
The data were nalysed using SPSS version 14 
for Windows (SPSS Inc, Chicago, IL, USA). Normal 
distribution of continuous variables was assessed by 
Kolmogorov–Smirnov test or by histograms. Normal 
distributed continuous variables were expressed as 
mean ± SD, those without normal distribution as me-
dian values. Student’s t-test was applied to compare 
continuous values with Gaussian distribution, while 
Mann–Whitney U-test was used for not normal dis-
tributed values. A p value below 0.05 was considered 
statistically significant. One-way ANOVA test was used 
to compare several mean values. To compare parametric 
data, Fisher’s exact test was applied. Pearson or Spear-
man correlation tests were used as appropriate. To 
estimate the cumulative incidence of a binary event, 
a Kaplan–Meier survival curve was applied (95% con-
fidence interval). 
Results
Demographic data
Using the established diagnostic criteria during AMD 
treatment, the patients were divided into three groups: 
a euthyroid group (n = 141, 61.5%), a hypothyroid 
group (n = 41, 17.9%), and a thyrotoxic group (n = 47, 
20.6%). 
Most of the patients received AMD therapy for 
supraventricular arrhythmias (n = 192, 83.8%), and 
only 37 for ventricular arrhythmias. The underlying 
cardiac diseases were as follows: coronary heart disease 
(36.4%), hypertensive cardiomyopathy (18.4%), mixed 
cardiomyopathy (25.3%), valvular disease (16.5%), 
Wolff–Parkinson–White syndrome (three cases), atrial 
septal defect (one case) and hypertrophic obstructive 
cardiomyopathy (three cases).
The screening of thyroid function before introducing 
AMD treatment (at least TSH determination) was per-
formed in 139 cases (60.6%) (Table I). The non-screened 
patients were evaluated during AMD treatment as soon 
as they entered the study. The euthyroid status during 
AMD therapy was confirmed in all patients who sub-
sequently developed thyroid dysfunction.
After the initial evaluation, the hormonal investiga-
tions were repeated after three months. The new values 
were considered new reference values. Thereafter, the 
Table I. Baseline thyroid screening in studied cases
Tabela I. Wyniki wyjściowych badań tarczycy u osób badanych
Parameter Baseline screened cases
Complete thyroid evaluation
Thyroid examination
Thyroid ultrasonography
TSH, FT4, FT3
Antithyroid antibodies
58 (25.3%)
Clinical examination + TSH 81 (35.3%)
Not evaluated 90 (39.4%)
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patients were evaluated every six months by TSH deter-
mination. The patients were evaluated immediately in 
case of arrhythmia during AMD therapy or if a thyroid 
dysfunction was suspected. 
Women predominated in the hypothyroid group 
compared to the thyrotoxic group (p = 0.053, Fisher ’s 
exact test). The AIT group was significantly younger 
compared to the euthyroid and the hypothyroid 
group (57.5 ± 8.2 years, vs. 64.8 ± 9.4 years and 
respectively 66.0 ± 7.4 years, p < 0.001, t test). No 
statistically significant differences were noticed 
among study groups regarding mean duration of 
AMD treatment, mean daily dose, cumulative dose 
of AMD, or serum concentrations of AMD and DEA 
(measured in 113 patients) (Table II).
Thyroid dysfunction group parameters
The overt form prevailed in the AIT group (44/47) but not 
in the AIH group (12/41) (p < 0.001, Fisher’s exact test). 
Within the entire study group, 68 patients presented 
goitres: 11 nodular goitres and 57 diffuse goitres, with 
a similar percentage between women (n = 35) and men 
(n = 33).
The prevalence of goitre was significantly higher in 
the thyroid dysfunction group (n = 43, 48.8%), com-
pared to the euthyroid group (n = 25, 17.7%, p < 0.0001, 
Fisher’s exact test).
Thyrotoxic patients presented higher thyroid vol-
umes (median volume 23 ml, limits 11–45 ml) compared 
to hypothyroid (median 16.7 ml, limits 7–40 ml) and eu-
thyroid cases (median 15.8 ml, limits 9–38 ml) (p = 0.001, 
Anova test) (Table I).
In the AIT group, the mean age, the duration of 
AMD treatment until thyrotoxicosis developed, and the 
cumulative dose were similar among the pathogenic 
subgroups. Type 2 and mixed AIT patients were younger 
compared to type 1 (56.3 ± 8.07 years, respectively 
55.3 ± 10.2 vs. 62.0 ± 3.9 years, p = 0.052 and respec-
tively p = 0.06) (Table III).
One AIT diagnosis criterion was thyroid abnormali-
ties. Thus, ten patients classified as type 1 AIT showed 
diffuse (seven cases) or nodular goitre. Seven patients 
were diagnosed as type 2, and 13 mixed forms presented 
diffuse goitre.
The prevalence of positive antithyroid antibodies 
was higher in the thyroid dysfunction group (22 cases, 
25%) compared to the euthyroid group (22 cases, 15.6%, 
p = 0.08 Fisher’s exact test).
Of the eight type 1 thyrotoxic patients with diffuse 
goitre, five presented positive titres of TRAb, unlike 
the other subgroups, where none of the patients had 
positive TRAb values.
A percentage of 14.7 of thyroid dysfunction cases 
presented previous thyroid pathology, as compared 
to 9.2% of euthyroid subjects. In the type 1 AIT group, 
six patients presented thyroid abnormalities: three 
nodular goitres and three diffuse goitres. In the mixed 
form group, three patients presented formerly known 
diffuse goitre, unlike type 2, with two cases of known 
thyroid abnormalities. 
Table II. Demographic, clinical and biochemical data in study groups (quantitative data expressed as mean ± SD)
Tabela II. Demograficzna, kliniczna i biochemiczna charakterystyka badanych grup (dane ilościowe przedstawiono jako 
wartości średnie ± SD)
Parameter Euthyroid group AIH group AIT group p
Number of patients 141 41 47
Gender (women/men) 74/67 24/17 17/30 0.076‡
Age (years) 64.8 ± 9.4 66.0 ± 7.4 57.5 ± 8.2 < 0.0001†
Duration of AMD therapy (months) 26.0 ± 24 23.7 ± 17.5 26.3 ± 16.4 0.82*
Median 18 17 24.5
Cumulative dose of AMD [g] 152.4 ± 143.7 141.4 ± 98.2 154.2 ± 96.7 0.87†
Serum AMD concentration [µg/L] 666.5 ± 358.3 755.7 ± 472.2 558.8 ± 362.2 0.33†
Serum DEA concentration [µg/L] 663.4 ± 325.1 687.8 ± 303.7 525.5 ± 342.1 0.26†
Goitre at diagnosis (n)
    Diffuse 17 15 27 < 0.0001‡
    Nodular 8 0 3
Thyroid volume [ml] 19.2 ± 7.1 17.2 ± 7.2 24.0 ± 8.3 0.001†
Positive antithyroid antibodies (n, %) 22 (15.6%) 11 (26.8%) 11 (23.4%) 0.19‡
†One-way Anova test; ‡ c2 test; *non-parametric Mann–Whitney U-test
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Clinical data and arrhythmias
Most of the thyrotoxic patients, regardless of the patho-
genic subtype, presented with major clinical symptoms: 
palpitations, mild weight loss, marked fatigue, tremor 
and dyspnoea. The clinical picture of the overt hypo-
thyroid patients was unremarkable, with complaints 
mostly only consisting of asthenia and somnolence. 
Subclinical dysfunction cases were diagnosed by routine 
laboratory tests. 
Three quarters of the thyrotoxic patients presented 
arrhythmias (new-onset or recurrent): 24 cases of 
atrial fibrillation, six of atrial flutter, and five cases with 
ventricular extrasystolia. The mean age of AIT patients 
with arrhythmias was similar to that of AIT subjects 
without arrhythmias (58.3 ± 7.0 years, vs. 54.3 ± 11.3 
years, p = 0.16, t test). 
No statistically significant differences were no-
ticed regarding duration, cumulative dose or serum 
AMD and DEA concentration between the arrhyth-
mic group and the sinus rhythm group. Thyrotoxic 
arrhythmic patients presented significantly lower 
values of TSH (mean 0.004 ± 0.005 mU/L, median 
0.001 mU/L) compared to the non-arrhythmic group 
(mean 0.011 ± 0.008 mU/L, median 0.01 mU/L, 
p = 0.02, t test), associated with comparable serum 
FT3 and FT4 values.
Euthyroid and hypothyroid patients developed dif-
ferent arrhythmias, but at a smaller rate than AIT cases 
(22, respectively 7 cases) (p < 0.0001, c2 test). 
Risk factors for thyroid dysfunction
As 38.4% of the patients developed thyroid dysfunction, 
the present study tried to establish the risk factors for 
developing a future thyroid disease.
The pattern of thyroid dysfunction development 
was heterogeneous (4–84 months).
The duration of AMD treatment until thyro-
toxicosis developed was 26.3 ± 16.4 months (me-
dian 24.5 months). The rate of diagnosis was as 
follows: 25% at 13 months, 50% at 24 months, and 
75% at 35 months. Hypothyroidism developed after 
23.7 ± 17.5 months (median 17 months), the rate being 
similar to that of AIT (p = 0.749, Log rank Mantel-Cox 
test) (Figure 1). The rate of diagnosis was similar among 
pathogenic types of AIT.
The thyroid dysfunction group included 47 men 
and 41 women. Women developed thyroid dysfunc-
tion slightly earlier (mean 22.8 ± 17.4 months, median 
16 months), compared to men (mean 26.8 ± 16.6 months, 
median 24 months), but the rate of diagnosis was similar 
(p = 0.301, Log Rank Mantel-Cox test).
The patients with previous thyroid abnormali-
ties (diffuse or nodular goitre, positive antithyroid 
antibodies) developed thyroid dysfunction earlier 
(mean 18.2 ± 13.1 months, 95% confidence interval 
12.7–23.8 months, median 14.5 months) compared 
to those without pre-existing thyroid abnormalities 
(26.2 ± 17.2 months, 95% confidence interval 22.0–
–30.5 months, median 24 months, p = 0.04, t-test).
The Log Rank Mantel-Cox test (p = 0.003) proved 
that the rate of diagnosis differed significantly in the 
group with thyroid abnormalities (25% at 11 months, 
50% at 24 months, 75% at 36 months), compared to 
the group without pre-existing alterations (25% at 
24 months, 50% at 42 months, 75% at 72 months).
The patients with positive antithyroid antibodies 
presented similar diagnosis rate of thyroid dysfunction 
as those with negative antibodies. However, those with 
Table III. AIT group parameters (values expressed as mean ± SD)
Tabela III. Badane parametry w grupie AIT (dane przedstawiono jako wartości średnie ± SD)
Parameter Type 1
(11 cases)
Type 2
(15 cases)
Mixed form
(21 cases)
p
Age (years) 62.0 ± 3.9 56.3 ± 8.07 55.3 ±10.2 0.13†
Duration of AMD treatment (months) 26.9 ± 19.8 31.07 ± 17.7 21.3 ± 11.4 0.43‡
Cumulative dose of AMD [g] 160.8 ± 115.5 170.8 ± 110.8 133.0 ± 63.8 0.84‡
Thyroid volume [ml] 30.0 ± 8.2 18.6 ± 5.5 24.8 ± 7.9 0.005†
Goitre at diagnosis (n) 10 7 13 0.064*
Previous thyroid abnormalities (n) 6 2 3 0.02*
Positive antithyroid antibodies (n) 7 0 4 0.0006*
TSH [mU/L] 0.007 ± 0.006 0.008 ± 0.009 0.011 ± 0.01 0.71†
FT4 [ng/dl] 4.65 ± 1.68 4.25 ± 1.59 4.41 ± 1.74 0.85
†
FT3 [pg/ml] 6.62 ± 1.85 6.2 ± 2.86 9.26 ± 6.11 0.18
†
†One-way Anova test; ‡Kruskal–Wallis test; *c2 test
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very high titres of antibodies developed the dysfunc-
tion earlier than those with low or negative titres, even 
though no statistically significant differences were 
noticed (p = 0.50, Log Rank Mantel-Cox test).
The age of the patients, the daily dose of AMD, the 
cumulative dose, the serum AMD and DEA concentra-
tions, did not influence significantly the rate of thyroid 
dysfunction development.
Discussion
The incidence of thyroid dysfunction induced by AMD 
reported in the present study is similar to that in the 
literature, with a slightly higher percentage of the AIT, 
as previously reported [7, 11]. 
The incidence and severity of newly diagnosed 
thyroid dysfunctions are influenced by the screening 
and monitoring of patients. 
A complete thyroid evaluation should be performed 
prior to AMD treatment to identify the subjects with risk 
factors for a possible future dysfunction. Additionally, 
in patients with nodular goitre, thyroid scintigraphy 
should be performed, even if TSH is normal.  
Where morphological (diffuse or nodular goitre) or 
immunological (positive serum antithyroid antibody) 
abnormalities are detected, monitoring should be in-
dividualised, these cases presenting an increased risk 
for future thyroid dysfunction. 
The prevalence of positive antithyroid antibodies 
was slightly higher in the AIH group (26.8%) compared 
to the euthyroid (15.6%) and the AIT groups (23.4%). 
In some patients, the titres appear to influence the oc-
currence of AIH, subjects with high titres developing 
the dysfunction earlier.
Patients with a serum TSH value at the upper limit of 
normal and/or positive antithyroid antibodies present an in-
creased risk for the development of hypothyroidism [32].
Our screening rate was suboptimal (39.4% of the 
cases had not been evaluated before AMD treatment). 
The reported screening rate varies from 37% to 65.8% 
[33] and the rate of proper monitoring is also very 
heterogeneous, ranging from 2.9% [30] to 72.7% 
[21]. In order to increase patients’ compliance with 
the monitoring process, it is necessary to develop 
an interdisciplinary algorithm. Figure 2 represents 
our proposed algorithm for screening and monitoring 
AMD-treated patients.
The rates of diagnosis of AIH and AIT were similar 
in our study. Some authors have reported a specific 
pattern: while AIT can develop at any time during 
AMD therapy, AIH occurs usually in the first months 
of treatment [8]. Other studies have reported a random 
pattern of occurrence, but with increasing incidence of 
AIT over time [7]. In the present study, the pattern of 
development of thyroid dysfunction was very hetero-
geneous (4–84 months).
The higher prevalence of subclinical AIH over the 
clinical form in our study group could be due to low 
progress of the subclinical form into the overt one. 
Figure 2. Algorithm for following AMD-treated cases
Rycina 2. Algorytm obserwacji chorych leczonych AMD
Figure 1. Kaplan–Meier survival curve, representing the 
cumulative risk of thyroid dysfunction development and the period 
of time until diagnosis
Rycina 1. Krzywe przeżycia Kaplana-Meiera przedstawiające 
skumulowane ryzyko zaburzeń czynności tarczycy i czas do 
dokonania rozpoznania
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The increasing incidence of AIT in iodine-replete 
areas suggests other possible pathogenic mechanisms, 
independent of iodine intake: thyroid autoregulation 
alteration induced by iodine, direct cytotoxic effects of 
AMD on thyroid follicles, specific genes, or increased 
susceptibility of some subjects to develop thyrotoxicosis 
[10, 24, 34]. 
A retrospective study by Bogazzi which included 
215 patients with AIT (over 27 years) revealed 
a change in the prevalence of pathogenic types of 
thyrotoxicosis. The incidence of type 2 increased, 
while type 1 remained constant. The increasing 
incidence of type 2 could be explained by more care-
ful screening and monitoring in recent years, the 
administration of AMD for longer periods, and the 
avoidance of AMD treatment in patients with thyroid 
abnormalities [35, 36].
The increasingly sensitive methods for determining 
TSH have led to an improved diagnosis of subclinical 
dysfunction. Minor dysfunction (subclinical hyper-
thyroidism) may become clinically significant in some 
patients, especially in those with heart disease, who 
are particularly susceptible to minor changes in thyroid 
functionality.
AIT classification in pathogenic forms was per-
formed taking into account several criteria (clinical, 
laboratory data, therapeutic response). Quantification 
of thyroid parenchymal vascularity by colour Doppler 
ultrasound represents an important tool in the assess-
ment of these cases.
There is no consensus regarding the diagnostic 
criteria of thyroid dysfunction induced by AMD. 
A survey of European thyroidologists (affiliated to 
the European Thyroid Association) and thyroidolo-
gists from Latin America presented heterogeneous 
opinions, in part because of different iodine intake, 
and hence different reported incidences of thyroid 
dysfunction [35–37].
Since 74.4% of AIT patients, and 17% of those 
with hypothyroidism, presented arrhythmias, 
thyroid functionality should be evaluated in any 
patient who develops arrhythmias during AMD 
treatment. 
Although serum FT3 values were similar in both 
thyrotoxic arrhythmic and non-arrhythmic patients, 
TSH concentrations were significantly lower in 
those who developed arrhythmias. Several studies 
have confirmed that suppressed TSH is involved 
in triggering supraventricular arrhythmias [38–40]. 
The degree of TSH suppression is a major determi-
nant in the occurrence of arrhythmias, since their 
prevalence is higher in hyperthyroidism compared to 
euthyroidism, but is similar in overt and subclinical 
hyperthyroidism [41–44].
Conclusions
In a cohort of 229 AMD-treated patients from an io-
dine-replete area, 38.4% developed thyroid dysfunction: 
17.9% hypothyroidism and 20.4% thyrotoxicosis. The 
main risk factors for AMD-induced thyroid dysfunc-
tion are represented by previous thyroid pathology 
(diffuse goitre, nodular goitre, and antithyroid antibod-
ies). Such cases require systematic monitoring. Most 
of the thyrotoxic patients presented the overt form, 
while in the hypothyroid group, the subclinical form 
prevailed. The AIT group was dominated by type 2 
and mixed forms. Although the classification of AIT 
cases in pathogenic types is important in terms of the 
therapeutic approach, there are still many cases which 
pose complex diagnostic difficulties. 
The daily dose, the duration of the treatment, and 
the cumulative dose of AMD do not represent risk fac-
tors for the development of thyroid dysfunction. The 
determination of serum AMD and desethylamiodarone 
concentrations does not offer supplementary benefits 
in the diagnosis and treatment of thyroid dysfunction.
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